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Mineralocorticoid activity and the excretion of an oral potassium load
in normal man. In six healthy males on a fixed sodium/potassium
(Na/K) intake, we studied the relation between plasma K and urine K
and Na excretion after an oral K load. Studies were repeated during
fludrocortisone (0.5 mg bid) or spironolactone (50 mg qid), that is, after
escape from the Na-retaining and Na-excreting effects of these drugs. A
steep positive relation between plasma K (ordinate) and urine K or Na
(abscissa) was found, compatible with a strong influence of changes in
plasma K on K and Na excretion. Fludrocortisone reset the relation to
a lower level of plasma K. Spironolactone, on the other hand, had little
effect on these relations, although a tendency towards a higher plasma
K could be recognized. Paradoxically, the K load was excreted less
efficiently during fludrocortisone, probably due to enhanced cellular K
deposition. Prolonged kaliuresis relative to the transient rise in plasma
K and natriuresis was found only without medication. Only in this
situation aldosterone rose and fell parallel to plasma K. We conclude
that: 1) chronic mineralocorticoid increase shifts the set point of both K
and Na excretion following a K load to a lower plasma K, compatible
with resetting of the positive influence of plasma K on distal solute
delivery towards a lower plasma K; 2) total kaliuresis is paradoxically
low due to enhanced cellular K uptake; 3) blockade of endogenous
aldosterone action has relatively little influence on these relations
between plasma K and urine K or Na; 4) the contribution of acute
aldosterone stimulation to the excretion of a single oral K load can be
recognized as a delayed kaliuresis extending beyond the peak in plasma
K.
The rapid increase in renal potassium (K) excretion after an
acute K load is multifactorial. Of prime importance is probably
the rise in plasma K, which directly stimulates K secretion in
distal nephron segments [1, 21. In addition, there is evidence
that the rise in plasma K attenuates NaCI reabsorption in the
proximal tubule [3, 4], whereas attenuated reabsorption in
Henle's loop has been found as well [5, 61. This would also
promote kaliuresis by increased distal sodium (Na) and fluid
delivery [7, 81, and account for the often observed natriuretic
effect of a K load [9—1 1]. Also, an acute increase in K delivery
out of Henle's loop has been found [12]. Finally, the rise in
plasma K stimulates aldosterone release, also in favor of
kaliuresis [13, 14].
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How chronic changes in aldosterone affect the renal handling
of an acute K load is not completely clear. Sustained aldoste-
rone elevation facilitates kaliuresis, resulting in K balance at a
lower plasma K [15]. It has been emphasized that aldosterone
increases Na ,K-ATPase in the late distal and cortical collect-
ing tubules [16], making that higher rates of Na reabsorption
and K secretion are accomplished at a given plasma K [8, 17].
However, excretion of a single K load also involves the
mentioned rapid rise in Na delivery to these segments, manifest
in vivo by rapid natriuresis besides kaliuresis. It is not clear
whether this also occurs after adaptation to a sustained rise in
aldosterone [18, 19]. In a recent study in adrenalectomized rats,
the Na excretion following KCL infusion was much lower
during high-constant aldosterone replacement than during nor-
mal-constant replacement [20]. However, the kaliuresis seemed
attenuated as well, probably due to the high-constant aldoste-
rone which enhances extrarenal deposition of a K load [20, 21].
This may have attenuated the rise in plasma K in these studies,
and, consequently, the rise in urine K and urine Na [20, 22]. If,
on the other hand, during mineralocorticoid adaptation an acute
K load would still lead to a rapid increase in K and Na excretion
in proportion to the rise in plasma K, this would confirm that
acute influences of plasma K on Na reabsorption prior to the
distal nephron and on K excretion are reset to a lower level of
plasma K. Such facilitation by aldosterone of both K and Na
excretion after a K load could best be studied by analyzing the
acute temporal relations between these two variables and
plasma K following a K load.
Analysis of the role of immediate changes in plasma K in
accelerating K and Na excretion after an acute K load is
complicated by the fact that the transient rise in K but not in Na
excretion lasts longer than the rise in plasma K, as was shown
recently in sheep [23]. Although direct evidence was not
provided in that study, it was considered that this prolonged
kaliuresis, occurring in spite of an again falling plasma K, was
due to stimulation of aldosterone [23], which is known to have
a delayed effect on the kidney [24]. If this were the case,
information on the direct effect of plasma K on Na and K
excretion can be obtained only early after the K load. More-
over, kaliuresis outlasting the rise in plasma K and natriuresis
would not be seen when a K load is taken during constant
mineralocorticoid action.
We therefore studied the relation between plasma K and
renal K, and Na excretion after an acute oral K load in six
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Table 1. Steady state data before clearance studies
No drug Fludrocortisone Spironolactone
Body weight kg 76.0 2.3 78.2 2.9 74.2 22
Plasma sodium mmol/liter 144 1 148 1" 140 U'
Plasma potassium mmol/liter 4.0 0.1 3.0 4.3 0.2°
Plasma chloride mmol/liter 104 0 106 1° 103 1
Plasma bicarbonate mmollliter 27.0 0.5 29.5 09 25.0 0.9
Plasma aldosterone pmol//iter 310 60 100 2O 1130 3W'
Plasma renin activity fmol/liter/sec 530 150 40 10" 1690 300"
Urine sodium mmol/24 hr 86 3 85 7 86 2
Urine potassium mmolI24 hr 70 6 74 3 76 3
Urine chloride mmolI24 hr 89 8 92 6 87 3
Inulin clearance mI/mm 104 6 124 6" 98 4
Significant differences from data without medication are indicated by a P C 0.05, and "P C 0.01.
healthy males. The experiments were repeated after two weeks
of fiudrocortisone and two weeks of spironolactone. Specific
questions were: 1) whether chronic increase or decrease in
mineralocorticoid activity would shift the acute relation be-
tween plasma K and kaliuresis or natriuresis to, respectively,
lower or higher levels of plasma K; and 2) whether the pro-
longed kaliuresis after a single K load represents a delayed
effect of acute aldosterone stimulation.
Methods
Studies were carried out in six healthy males (mean age 24,
range 21 to 31 yrs), with informed consent and after approval of
the Hospital Ethical Committee for Study in Humans. The
general outline of the study was as follows: after four days of a
diet containing 100 mmol NaJlOO mmol K, clearance studies
were performed on day 5 (control study) and 7 (K-load study).
The diet was provided by our metabolic ward, where the
subjects paid daily visits to deliver 24-hour urine collections, to
measure body weight, and to undergo the clearance studies.
After this first part of the study the diet was free, and fludro-
cortisone (0.5 mg bid orally) was started. After two weeks the
100 mmol NaJlOO mmol K diet was restarted while fiudrocorti-
sone was continued, and again clearance studies performed on
days S and 7. Fludrocortisone was then replaced by spironolac-
tone (50 mg qid orally), and after another two week period of
free diet the studies were performed a third time under the same
dietary restrictions.
Clearance studies were performed between 8 a.m. and 3 p.m.
after an overnight fast and with continued recumbency. A
constant intravenous infusion of inulin preceded by a prime
dose was started at 8 a.m. Urine was collected hourly by
spontaneous voiding between 9 a.m. and 3 p.m., and blood
samples were taken halfway through each collection period. A
modest water load (150 ml hourly) was taken to ensure adequate
urine flow. The clearance study of day S served as control
study. On day 7 an acute K load (1 mmol/kg body wt in the form
of 1 mmol/ml KC1 solution) was taken orally at 10 a.m.
The clearance studies during fludrocortisone were done in the
same way. However, in pilot studies it had appeared that in
some subjects the action of this drug taken twice daily was not
constant over the day, even after a maintenance period of two
weeks. This might present a difficulty in interpreting our clear-
ance data. Therefore the frequency of drug intake was in-
creased on the day of the clearance studies: 0.5 mg was taken at
0, 4, 8, and 12a.m., which would ensure a more or less constant
and maximal drug action throughout the clearance studies. To
avoid dangerous hyperkalemia by the K load during spirono-
lactone, in this part of the study the dose was limited to 0.5
mmol/kg (which in pilot studies had appeared to result in similar
peak plasma K concentrations as the full dose did in the
absence of spironolactone). The last dose of spironolactone
prior to the clearance study was taken at 8 a.m. To prevent
decreased drug action during the clearance studies an additional
dose of spironolactone was given on the clearance days at 12
a, m.
Plasma and urine were analyzed for Na and K (Instrumenta-
tion Laboratory Autocal 743 flame photometer, Lexington,
Massachusetts, USA), Cl (Technicon RA- 1000 autoanlyzer,
Technicon Instruments Inc., Tarrytown, New York, USA) and
inulin. Inulin was hydrolyzed to fructose and determined pho-
tometrically with indolacetic acid [25]. Plasma renin activity
and aldosterone concentration were measured by radioimmu-
noassay [26].
Differences between steady state data before the clearance
studies were analyzed by one way analysis of variance (ANOVA,
randomized block design). If the variance ratio reached statis-
tical significance, the differences were analyzed by the method
of the least significant difference (LSD), using the ANOVA
mean square error to calculate the LSD [27]. Cumulative
electrolyte excretion and differences between clearance data of
control and K-load experiment were analyzed by two way
ANOVA (randomized block design) and LSD test. All data are
given as means standard error.
Results
Steady state data
Two weeks of fludrocortisone and two weeks of spironolac-
tone had the expected effects of, respectively, about a 2 kg
increase and decrease in body weight, accompanied by appro-
priate suppression and stimulation of plasma renin and aldoste-
rone (Table 1). The decrease in plasma K during fludrocortisone
was substantial, but the increase during spironolactone only
modest. Renal 24-hour Na excretion (Table 1 presents means of
the two days prior to the clearance studies) was slightly lower
than the calculated dietary supply. However, this was not
different after two weeks of fiudrocortisone or spironolactone,
and the subjects had evidently escaped from, respectively, the
Na-retaining and Na-excreting effects of these drugs. Excre-
tions of K and Cl were also comparable. Mean inulin clearance
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Fig. 1. Effects of an acute K load on plasma
K, on renal K and Na excretion and on inulin
clearance. C, one-hour collection period
before K load. Open bars, control study
without K load; stippled bars, study during K
load. Significant differences with control study
are indicated by * < 0.05. 0: note that
during spironolactone the K load was half (0.5
mmol KClIkg) of that given in the other two
studies (1 mmol/kg). Data given as means
standard error.
was increased after fludrocortisone, and slightly lowered (NS)
after spironolactone.
Effects of acute K loads
The oral K load (76 mmol in the studies without drug
pretreatment and during fludrocortisone, 38 mmol in the study
during spironolactone) induced transient increases in plasma K,
and urinary K and Na excretion, but no consistent change in
inulin clearance (Fig. 1). Maximum levels were found in the
second hour after the K load. Without drug pretreatment,
plasma K rose from 4.0 0.1 to a maximum of 5.1 0.1
mmollliter. Kaliuresis remained elevated until the fifth collec-
tion hour, while Na excretion had returned to control earlier.
After pretreatment with fludrocortisone, baseline plasma K was
3.0 0.1 and rose to a maximum of 3.7 0.1 mmol/liter, its
peak value remaining below the average level of the (no-steroid)
control study. The increase in K excretion tended to be less.
Kaliuresis increased and again decreased parallel with plasma
K, and thus was of shorter duration than without steroid
pretreatment. After pretreatment with spironolactone, plasma
K started from 4.3 0.1 mmol/liter, and after the K load (note
that the dose was only half that given in the former two studies)
rose to a maximum of 5.0 0.3 mmol/Iiter, a level comparable
to that found after K loading in the no drug study. However,
due to individual variation no difference with plasma K in the
corresponding control study was found according to the ANOVA.
As during fludrocortisone, kaliuresis rose and fell parallel to
plasma K.
During fludrocortisone only 37 5% of the K load was
excreted within the five hours after ingestion, compared to 85
4% under normal conditions (P < 0.001). Table 2, presenting
cumulative electrolyte excretions, shows that in particular the
rise in K and Cl excretion was attenuated during fludrocorti-
sone. During spironolactone 117 11% of the K load (half
dose) was excreted within the clearance study. Urine flow did
not differ during the K load studies: 153 11 ml/hr (no drug),
135 25 mI/hr (fludrocortisone), and 146 24 mI/hr (spirono-
lactone).
Figure 2 shows that a clear rise in plasma aldosterone,
peaking in the second hour after the K load, was only present
without steroid pretreatment. During fludrocortisone plasma
aldosterone showed no such rise, but remained elevated rela-
tive to the corresponding control study. During spironolactone
plasma aldosterone rose in both control and K load study, with
no statistical difference between these two studies. Plasma
renin activity, on average reduced during fludrocortisone and
elevated during spironolactone, displayed no consistent change
after the K load. [Urine K/Urine (Na + K)], a measure of
"distal Na/K exchange" [28], rose during the second half of the
clearance study performed without drug pretreatment, and
became significantly higher than in the corresponding control
study (Fig. 2). This was not observed during fludrocortisone or
spironolactone.
These data indicate that acute changes in plasma aldosterone
particularly influenced the relationship between plasma K and
renal K and Na excretion in the second half of the clearance
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Table 2. Cumulative electrolyte excretion during control and K-load clearance study
Potassium mmol/5 hr
Control
Sodium mmol/5 hr
K load A Control
Chloride mmol/5 hr
K load AControl K load A
Nodrug
Fludrocortisone
Spironolacton&'
24±3 65±4 41±3
16 3 29 4 13 4
30 4 44 4 14 3
32±5
36 9
35 8
62±8
55 16
52 11
30±7
19 II
18 9
23±4
25 6
33 8
73±9
44 l2
62 11
50±8
19 8
29 9
A means the difference between control and K-load study. Note that cumulative excretions of K, Na, and Cl after the K load were always
significantly higher than during the control study, which is not indicated in the table.
a P < 0.01 compared to no-drug studyb Statistical comparison with the no-drug study not performed since the K load was smaller during spironolactone.
studies. To eliminate this effect, the findings of the first two
collection periods were plotted separately (Fig. 3). This graph
shows that fludrocortisone shifted the curves relating plasma K
to urine K or Na to the left parallel to the normal curve,
implying that a given K or Na excretion was accomplished at a
lower plasma K. Statistical support for this shift follows from
the significant differences in plasma K at comparable levels of K
or Na excretion (Fig. 3). Less clearly, spironolactone shifted
the curves to the right, but this was no more than a tendency;
there was no significant difference in plasma K compared to the
normal situation, also at comparable K or Na excretion rates.
Discussion
Our main purpose was to assess the relations between plasma
K and renal K and Na excretion after an acute oral K load in
normal man. Specifically we were interested in how this relation
is affected in states of relative hyper- and hypo-mineralocor-
ticism, simulated by the use of fiudrocortisone and spirono-
lactone.
In normal conditions the K load caused transient increments
in plasma K and urine K which peaked in the second hour after
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ingestion. Over the next three hours the curves declined, but
the decrease in urine K lagged behind the decrease in plasma K
(Fig. 1). For humans such curves have not been presented, but
can be inferred from occasional published data [9, 10]. Rabino-
witz, Sarason and Yamauchi [231, studying the effects of acute
K infusion in sheep, found that K excretion rose with time in a
bimodal fashion: an immediate rise which fell back as soon as
infusion was stopped. This was followed by a second 'delayed
kaliuresis", which began within an hour from the start of the
infusion and continued while Na excretion, rising initially in
parallel with K excretion, returned to baseline [23]. Similarly,
we found that natriuresis initially kept pace with kaliuresis but
then declined to baseline while kaliuresis continued.
The natriuretic effect of potassium is known from human and
animal studies [9—11, 20, 22]. It has been ascribed to suppres-
sion of NaCl reabsorption in either the proximal tubule [3, 4] or
the thick ascending limb of Henle's loop [5, 6]. The resulting
rise in Na delivery to the late distal and collecting tubules would
promote renal K excretion [7, 8]. The rise in plasma K is the
probable driving force for this altered Na handling, but the
exact mechanism remains unclear. Apparently the natriuresis of
a single K load ends sooner than the kaliuresis (Fig. 1). This
dissociation between renal K and Na excretion is illustrated by
the ratio [Urine K/Urine (Na + K)], which was increased in (but
not before) the third hour after the K load (Fig. 2). The rise in
this ratio, which roughly represents "distal Na/K exchange"
[28], probably reflects the delayed action of aldosterone. Plas-
ma aldosterone, rising independently from plasma renin activity
early after the K load, peaked about two hours before the peak
in [Urine K/Urine (Na + K)]. This corresponds with the
generally observed time lag between aldosterone administration
and the full expression of its biological effect in the kidney [24].
Assuming that endogenous aldosterone stimulation indeed in-
fluenced electrolyte excretion from the third hour onwards, the
impact of acute changes in plasma K on renal K and Na
excretion would best be studied before this time (Fig. 3).
During maintenance on fludrocortisone, that is after escape
from its Na-retaining effect, plasma K was decreased, but there
was no indication for continued K loss according to daily urine
K. The curve relating plasma K to urine K after ingestion of the
K load was as steep as in normal conditions, but shifted to the
left; a given renal K excretion rate was accomplished at a lower
plasma K, compatible with a functional change (Fig. 3). This
may concern local amplification of the direct influence of
plasma K on K secretion by the cortical collecting tubule, since
chronic administration of mineralocorticoids increase Na ,K-
ATPase, Na reabsorption and K secretion at this site [8, 16, 171.
A tendency for alkalosis (Table I) may have contributed to this
effect [29]. Since the natriuresis curve was shifted in the same
way as the kaliuresis curve, it must be considered that ampli-
fication of the negative influence of plasma K on solute reab-
sorption in a more upstream nephron level played at least an
additional role in the shift to the left of the kaliuresis. Validation
of this hypothesis is hampered as long as the nature of the
natriuretic effect of a K load and its role in the subsequent
kaliuresis is incompletely understood [30]. A shift to the left in
the plasma K/urine K curve was also found during supraphys-
iological aldosterone replacement in adrenalectomized dogs
[15]. In that study, however, plasma K was changed by chronic
changes in K intake, which itself may induce adaptations in
renal K handling [20].
Recently Stanton et al [20] reported that adrenalectomized
rats maintained on supranormal aldosterone are hypokalemic,
but in K balance. However, after an acute K challenge these
animals showed less rise in plasma K and less kaliuresis. This
finding, made earlier in dogs [22], is confirmed by our data, and
has been attributed to enhanced extrarenal deposition of the K
load due to increased mineralocorticoid activity and depletion
of cellular K [1, 20]. This hypothesis presumes enhanced K
uptake by extrarenal tissues, a view supported by other studies
in adrenalectomized rats. In these studies by Alexander and
Levinski [21], mineralocorticoid was found to attenuate the rise
in plasma K after a K load also when the load was given directly
after nephrectomy. The action of mineralocorticoids to stimu-
late intracellular shift of K has been suggested from other
studies as well [31], including observations in humans [32, 33].
In the latter studies, in patients with hypoaldosteronism fludro-
cortisone caused a fall in plasma K without change in external
K balance. An alternative explanation for the blunted kaliuresis
during fludrocortisone is decreased intestinal uptake of the K
load [34]. This possibility cannot be excluded in our study, but
does not explain the same attenuation in studies where the load
was given intravenously [20, 21]. This leaves us with the
paradox that during mineralocorticoid excess a given renal K
excretion rate is developed at a lower level of plasma K, but
nonetheless a K load is excreted less efficiently.
During fludrocortisone the K load induced no rise in plasma
aldosterone, although in the second hour after the load its level
tended to be higher than in the corresponding control study.
This may be explained by the marked suppression of plasma
renin activity and, probably, of angiotensin II, since it has been
found that at low plasma concentrations of angiotensin II the
stimulation of aldosterone by plasma K is attenuated [14].
Interestingly, neither delayed kaliuresis (Fig. 1) nor increase in
the ratio [Urine K/Urine (Na + K)] (Fig. 3) occurred, suggest-
ing that these findings in the normal conditions were indeed
related to endogenous aldosterone stimulation.
The weight loss and stimulation of plasma renin activity after
two weeks of spironolactone indicate blockade of aldosterone
activity. Na and K excretion, though, were not dissimilar from
the starting level and plasma K had only increased slightly. To
avoid dangerous hyperkalemia only half the K load was given in
this study. The increase in plasma K was about equal to that
observed with the full K load given during fludrocortisone,
indicating relatively less cellular K distribution during sup-
pressed mineralocorticoid function. In contrast to the findings
during fludrocortisone, the K load was excreted completely
within the observation period, in keeping with the idea of an
inverse relation between the immediate cellular K uptake and
renal excretion [20, 22]. However, since during spironolactone
only half the K load was given, this should be taken with
reserve.
After the K load plasma aldosterone tended to rise, but no
significant difference with the corresponding control study was
found. It appears unlikely that endogenous aldosterone stimu-
lation contributed to the rapid excretion of the K load during
spironolactone. Rather, since the kaliuresis started early after
the K load, and no delayed dissociation developed between
renal K excretion and plasma K (Fig. 1) or Na excretion (Fig.
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2), it appears likely that an effective kaliuresis developed
independently from an acute change in aldosterone.
The rise in plasma K during spironolactone was modest
compared to that caused by adrenalectomy in animals [20, 351,
or in comparison to plasma K in untreated patients with adrenal
failure [33, 36]. In addition, the present data show that spiro-
nolactone had at most a small effect on the acute relation
between plasma and urine K after an oral K load. This curve
was again steep, and in the observed range of kaliuresis the
corresponding plasma K tended to be higher than without
steroid treatment, but the difference was not significant. As an
explanation, incomplete blockade of renal actions of aldoste-
rone by spironolactone should be considered, particularly in
view of the elevated aldosterone in association with renin
stimulation, An alternative explanation pertains to the role of
glucocorticoids. Studies in adrenalectomized rats in which
either glucocorticoid or mineralocorticoid or both were sup-
pleted showed that both hormones are required for the normal
renal excretion of an acute K load [37]. Glucocorticoids con-
tribute to renal K excretion in a way not likely to be affected by
spironolactone [37]. In fact, it has been found that acute
administration of spironolactone in high dosages did not impair
the excretion of a K load [35, 38], in contrast to marked
impairment after adrenalectomy [35].
In sum, an oral K load in humans was soon followed by a rise
in plasma K and urine K and Na. The relation between plasma
K and urine K or Na was steep, suggesting that changes in
plasma K strongly and acutely modify K and Na excretion.
Fludrocortisone induced hypokalemia and shifted these acute
relations to a lower plasma K; spironolactone, on the other
hand, had only little effect on plasma K and its relation to K or
Na excretion. Apparently, chronic changes in mineralocor-
ticoid activity determine renal K handling, but other factors,
such as glucocorticoid activity, are important as well. Besides
the well-known promotion of K secretion in the distal nephron,
mirieralocotticoid seems to facilitate the rise in distal solute
delivery which occurs after an acute K load. Though the
mechanism of this event remains to be defined, it likely con-
tributes to the fact that after a single K load kaliuresis can be
increased rapidly at a low level of plasma K. Paradoxically,
excretion of an acute K load was blunted during maintenance
on fludrocortisone, probably due to enhanced extrarenal K
deposition. In normal conditions the kaliuresis outlasted the
rise in plasma K and natriuresis. This dissociation appears the
expression of delayed aldosterone action, and was not found
during fludrocortisone and spironolactone. In these latter situ-
ations the observed kaliuresis was probably independent of
endogenous aldosterone stimulation.
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